Búsqueda | Biblioteca Virtual en Salud

1.

Drug Pricing and Value in Oncology.

Danzon, Patricia M.

Recent Results Cancer Res ; 213: 153-167, 2019.

Artículo en Inglés | MEDLINE | ID: mdl-30543012

2.

Affordability Challenges to Value-Based Pricing: Mass Diseases, Orphan Diseases, and Cures.

Danzon, Patricia M.

Value Health ; 21(3): 252-257, 2018 03.

Artículo en Inglés | MEDLINE | ID: mdl-29566830

3.

Objectives, Budgets, Thresholds, and Opportunity Costs-A Health Economics Approach: An ISPOR Special Task Force Report [4].

Danzon, Patricia M; Drummond, Michael F; Towse, Adrian; Pauly, Mark V.

Value Health ; 21(2): 140-145, 2018 02.

Artículo en Inglés | MEDLINE | ID: mdl-29477391

4.

Defining Elements of Value in Health Care-A Health Economics Approach: An ISPOR Special Task Force Report [3].

Lakdawalla, Darius N; Doshi, Jalpa A; Garrison, Louis P; Phelps, Charles E; Basu, Anirban; Danzon, Patricia M.

Value Health ; 21(2): 131-139, 2018 02.

Artículo en Inglés | MEDLINE | ID: mdl-29477390

5.

Approaches to Aggregation and Decision Making-A Health Economics Approach: An ISPOR Special Task Force Report [5].

Phelps, Charles E; Lakdawalla, Darius N; Basu, Anirban; Drummond, Michael F; Towse, Adrian; Danzon, Patricia M.

Value Health ; 21(2): 146-154, 2018 02.

Artículo en Inglés | MEDLINE | ID: mdl-29477392

6.

A Health Economics Approach to US Value Assessment Frameworks-Summary and Recommendations of the ISPOR Special Task Force Report [7].

Garrison, Louis P; Neumann, Peter J; Willke, Richard J; Basu, Anirban; Danzon, Patricia M; Doshi, Jalpa A; Drummond, Michael F; Lakdawalla, Darius N; Pauly, Mark V; Phelps, Charles E; Ramsey, Scott D; Towse, Adrian; Weinstein, Milton C.

Value Health ; 21(2): 161-165, 2018 02.

Artículo en Inglés | MEDLINE | ID: mdl-29477394

7.

Pharmaceutical pricing in emerging markets: effects of income, competition, and procurement.

Danzon, Patricia M; Mulcahy, Andrew W; Towse, Adrian K.

Health Econ ; 24(2): 238-52, 2015 Feb.

Artículo en Inglés | MEDLINE | ID: mdl-24293058

8.

Value-based differential pricing: efficient prices for drugs in a global context.

Danzon, Patricia; Towse, Adrian; Mestre-Ferrandiz, Jorge.

Health Econ ; 24(3): 294-301, 2015 Mar.

Artículo en Inglés | MEDLINE | ID: mdl-24327269

9.

Specific Value Assessment Considerations.

Kamal-Bahl, Sachin; Towse, Adrian; Spurgin, Liz; Danzon, Patricia M.

Value Health ; 22(6S): S24-S28, 2019 06.

Artículo en Inglés | MEDLINE | ID: mdl-31200803

10.

Commercial importation of prescription drugs in the United States: short-run implications.

Danzon, Patricia M; Johnson, Scott J; Long, Genia; Furukawa, Michael F.

J Health Polit Policy Law ; 36(2): 295-316, 2011 Apr.

Artículo en Inglés | MEDLINE | ID: mdl-21543707

11.

Drug pricing and value in oncology.

Danzon, Patricia M; Taylor, Erin.

Oncologist ; 15 Suppl 1: 24-31, 2010.

Artículo en Inglés | MEDLINE | ID: mdl-20237214

12.

The Affordable Medicines Facility--malaria: killing it slowly.

Arrow, Kenneth J; Danzon, Patricia M; Gelband, Hellen; Jamison, Dean; Laxminarayan, Ramanan; Mills, Anne; Mwabu, Germano; Panosian, Claire; Peto, Richard; White, Nicholas J.

Lancet ; 380(9857): 1889-90, 2012 Dec 01.

Artículo en Inglés | MEDLINE | ID: mdl-23122218

13.

At what price?

Danzon, Patricia M.

Nature ; 449(7159): 176-9, 2007 Sep 13.

Artículo en Inglés | MEDLINE | ID: mdl-17851515

14.

Differential Pricing of Pharmaceuticals: Theory, Evidence and Emerging Issues.

Danzon, Patricia M.

Pharmacoeconomics ; 36(12): 1395-1405, 2018 12.

Artículo en Inglés | MEDLINE | ID: mdl-30062518

15.

Why sole-supplier vaccine markets may be here to stay.

Danzon, Patricia; Pereira, Nuno Sousa.

Health Aff (Millwood) ; 24(3): 694-6, 2005.

Artículo en Inglés | MEDLINE | ID: mdl-15886161

16.

Vaccine supply: a cross-national perspective.

Danzon, Patricia M; Pereira, Nuno Sousa; Tejwani, Sapna S.

Health Aff (Millwood) ; 24(3): 706-17, 2005.

Artículo en Inglés | MEDLINE | ID: mdl-15886165

17.

Productivity in pharmaceutical-biotechnology R&D: the role of experience and alliances.

Danzon, Patricia M; Nicholson, Sean; Pereira, Nuno Sousa.

J Health Econ ; 24(2): 317-39, 2005 Mar.

Artículo en Inglés | MEDLINE | ID: mdl-15721048

18.

Alternative strategies for Medicare payment of outpatient prescription drugs--Part B and beyond.

Danzon, Patricia M; Wilensky, Gail R; Means, Kathleen E.

Am J Manag Care ; 11(3): 173-80, 2005 Mar.

Artículo en Inglés | MEDLINE | ID: mdl-15786856

19.

Closing the doughnut hole: no easy answers.

Danzon, Patricia M.

Health Aff (Millwood) ; Suppl Web Exclusives: W4-405-8, 2004.

Artículo en Inglés | MEDLINE | ID: mdl-15451952

20.

Prices and availability of pharmaceuticals: evidence from nine countries.

Danzon, Patricia M; Furukawa, Michael F.

Health Aff (Millwood) ; Suppl Web Exclusives: W3-521-36, 2003.

Artículo en Inglés | MEDLINE | ID: mdl-15506157

Biblioteca Virtual en Salud

Hipertensión

Su selección (0)

Formato de exportación:

Exportar:

Drug Pricing and Value in Oncology.

Affordability Challenges to Value-Based Pricing: Mass Diseases, Orphan Diseases, and Cures.

Objectives, Budgets, Thresholds, and Opportunity Costs-A Health Economics Approach: An ISPOR Special Task Force Report [4].

Defining Elements of Value in Health Care-A Health Economics Approach: An ISPOR Special Task Force Report [3].

Approaches to Aggregation and Decision Making-A Health Economics Approach: An ISPOR Special Task Force Report [5].

A Health Economics Approach to US Value Assessment Frameworks-Summary and Recommendations of the ISPOR Special Task Force Report [7].

Pharmaceutical pricing in emerging markets: effects of income, competition, and procurement.

Value-based differential pricing: efficient prices for drugs in a global context.

Specific Value Assessment Considerations.

Commercial importation of prescription drugs in the United States: short-run implications.

Drug pricing and value in oncology.

The Affordable Medicines Facility--malaria: killing it slowly.

At what price?

Differential Pricing of Pharmaceuticals: Theory, Evidence and Emerging Issues.

Why sole-supplier vaccine markets may be here to stay.

Vaccine supply: a cross-national perspective.

Productivity in pharmaceutical-biotechnology R&D: the role of experience and alliances.

Alternative strategies for Medicare payment of outpatient prescription drugs--Part B and beyond.

Closing the doughnut hole: no easy answers.

Prices and availability of pharmaceuticals: evidence from nine countries.